CAH · Company research
Cardinal Health, Inc. (CAH): Stock News & Events
Recent company-linked news records available in the database.
RESEARCH CONTEXT
Understand the numbers
Recent company-linked news records available in the database. Use period, currency, units and source fields when interpreting values.
44records availableHealthcare
Stock News & Events data
Database-backed records only
| title | summary | url | source | published at | sentiment | sentiment score | relevance score |
|---|---|---|---|---|---|---|---|
| CAH Oct 2026 205.000 put (CAH261016P00205000) Stock Price, News, Quote & History - Yahoo! Finance Canada | CAH Oct 2026 205.000 put (CAH261016P00205000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 16, 2026 | neutral | 0 | 0.6 |
| CAH Mar 2027 190.000 put (CAH270319P00190000) Stock Historical Prices & Data - Yahoo! Finance Canada | CAH Mar 2027 190.000 put (CAH270319P00190000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Cardinal Health (CAH) Laps the Stock Market: Here's Why - Yahoo Finance | Cardinal Health (CAH) Laps the Stock Market: Here's Why Yahoo Finance | View source ↗ | Yahoo Finance | Oct 15, 2026 | neutral | 0 | 0.6 |
| Cardinal Health (CAH) Laps the Stock Market: Here's Why | Cardinal Health (CAH) gained 2.41% in recent trading, outperforming the S&P 500. The prescription drug distributor is expected to report earnings of $2.92 per share on November 5, 2026, representing 14.51% year-over-year growth, with revenue projected at $66.96 billion. The stock holds a Zacks Rank #2 (Buy) rating, though it trades at a premium valuation with a Forward P/E of 19.75 compared to its industry average of 17.67. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| Cardinal Health (CAH) Laps the Stock Market: Here's Why | Cardinal Health (CAH) gained 2.41% in recent trading, outperforming the S&P 500. The prescription drug distributor is expected to report earnings of $2.92 per share on November 5, 2026, representing 14.51% year-over-year growth, with revenue projected at $66.96 billion. The stock holds a Zacks Rank #2 (Buy) rating, though it trades at a premium valuation with a Forward P/E of 19.75 compared to its industry average of 17.67. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| CAH Nov 2026 265.000 call (CAH261106C00265000) Interactive Stock Chart - Yahoo! Finance Canada | CAH Nov 2026 265.000 call (CAH261106C00265000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge | With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| 3 Low-Beta Defensive Stocks to Buy as Inflation Continues to Surge | With September CPI rising 3.7% year-over-year and inflation concerns potentially triggering additional Fed rate hikes, the article recommends three low-beta defensive healthcare stocks: Cardinal Health (CAH), UnitedHealth Group (UNH), and Corcept Therapeutics (CORT). These stocks offer lower market volatility and strong earnings growth prospects in an uncertain economic environment. | View source ↗ | Zacks Investment Research | Oct 15, 2026 | bullish | 1 | 1 |
| CAH Oct 2026 205.000 call (CAH261030C00205000) Interactive Stock Chart - Yahoo! Finance Canada | CAH Oct 2026 205.000 call (CAH261030C00205000) Interactive Stock Chart Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| AbbVie vs. Pfizer: Which Healthcare Stock Is a Better Buy in 2026? | AbbVie and Pfizer are compared as healthcare investment options in 2026. AbbVie has successfully navigated patent cliff challenges with strong growth from Skyrizi and Rinvoq offsetting Humira losses, while Pfizer is rebuilding its pipeline around obesity drugs and awaiting key pipeline readouts. The article recommends AbbVie as the clearer choice for investors seeking current pharmaceutical exposure, though both companies face biosimilar competition and regulatory pressures. | View source ↗ | The Motley Fool | Oct 15, 2026 | bullish | 0.2 | 1 |
| CAH Jun 2027 180.000 put (CAH270617P00180000) Stock Historical Prices & Data - Yahoo! Finance Canada | CAH Jun 2027 180.000 put (CAH270617P00180000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| CAH Jun 2027 180.000 put (CAH270617P00180000) Stock Price, News, Quote & History - Yahoo! Finance Canada | CAH Jun 2027 180.000 put (CAH270617P00180000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 15, 2026 | neutral | 0 | 0.6 |
| Cardinal Health Inc (CAH) Shares Surge 3.4% -- What GF Score of 78 Tells Investors - GuruFocus | Cardinal Health Inc (CAH) Shares Surge 3.4% -- What GF Score of 78 Tells Investors GuruFocus | View source ↗ | GuruFocus | Oct 14, 2026 | neutral | 0 | 0.6 |
| CAH Oct 2026 215.000 call (CAH261030C00215000) Stock Price, News, Quote & History - Yahoo! Finance Canada | CAH Oct 2026 215.000 call (CAH261030C00215000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 14, 2026 | neutral | 0 | 0.6 |
| Here's Why Cardinal Health (CAH) is a Strong Growth Stock | Cardinal Health (CAH) has been identified as a #2 (Buy) on the Zacks Rank with an A VGM Score. The healthcare services provider is forecasted to achieve 11.5% year-over-year earnings growth for the current fiscal year, with three analysts revising earnings estimates higher in the last 60 days. The company boasts a strong Growth Style Score of A and an average earnings surprise of +14.7%. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Here's Why Cardinal Health (CAH) is a Strong Growth Stock | Cardinal Health (CAH) has been identified as a #2 (Buy) on the Zacks Rank with an A VGM Score. The healthcare services provider is forecasted to achieve 11.5% year-over-year earnings growth for the current fiscal year, with three analysts revising earnings estimates higher in the last 60 days. The company boasts a strong Growth Style Score of A and an average earnings surprise of +14.7%. | View source ↗ | Zacks Investment Research | Oct 13, 2026 | bullish | 1 | 1 |
| Should Value Investors Buy Cardinal Health (CAH) Stock? - Yahoo Finance | Should Value Investors Buy Cardinal Health (CAH) Stock? Yahoo Finance | View source ↗ | Yahoo Finance | Oct 13, 2026 | neutral | 0 | 0.6 |
| China Patient Examination Devices Market Size, Share, and Forecast to 2033 - Thermometers and Stethoscopes | Pricing Trends and Growth Opportunities Guide Expansion | A comprehensive market report on China's patient examination devices market covering thermometers and stethoscopes through 2033. The report provides revenue, volume, and pricing data for medical device manufacturers, investors, and healthcare stakeholders, with 2025 company share analysis and competitive intelligence on key market players. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | neutral | 0 | 1 |
| China Patient Examination Devices Market Size, Share, and Forecast to 2033 - Thermometers and Stethoscopes | Pricing Trends and Growth Opportunities Guide Expansion | A comprehensive market report on China's patient examination devices market covering thermometers and stethoscopes through 2033. The report provides revenue, volume, and pricing data for medical device manufacturers, investors, and healthcare stakeholders, with 2025 company share analysis and competitive intelligence on key market players. | View source ↗ | GlobeNewswire Inc. | Oct 9, 2026 | neutral | 0 | 1 |
| CAH Oct 2026 207.500 put (CAH261009P00207500) Stock Price, News, Quote & History - Yahoo! Finance Canada | CAH Oct 2026 207.500 put (CAH261009P00207500) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 8, 2026 | neutral | 0 | 0.6 |
| CAH Oct 2026 210.000 put (CAH261030P00210000) Stock Historical Prices & Data - Yahoo! Finance Canada | CAH Oct 2026 210.000 put (CAH261030P00210000) Stock Historical Prices & Data Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 7, 2026 | neutral | 0 | 0.6 |
| CAH Oct 2026 210.000 put (CAH261009P00210000) Stock Price, News, Quote & History - Yahoo! Finance Canada | CAH Oct 2026 210.000 put (CAH261009P00210000) Stock Price, News, Quote & History Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 6, 2026 | neutral | 0 | 0.6 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Reasons to Retain Cardinal Health Stock in Your Portfolio for Now | Cardinal Health (CAH) expects Pharma profit growth of 8-11% in fiscal 2027 despite normalized demand, with other businesses projected to grow 15-18%. The company benefits from strong operational efficiency and specialty pharmaceutical growth, but faces headwinds from IRA pricing changes, moderating Specialty growth, and commodity cost pressures in its GMPD segment. | View source ↗ | Zacks Investment Research | Oct 6, 2026 | bullish | 0.75 | 1 |
| Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? | Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation. | View source ↗ | The Motley Fool | Oct 6, 2026 | bullish | 0.4 | 1 |
| Eli Lilly and vs. Novo Nordisk A/S: Which Healthcare Stock Is a Better Buy in 2026? | Eli Lilly and Novo Nordisk compete in the booming GLP-1 weight-loss and diabetes treatment market. Eli Lilly demonstrates superior growth with 44.7% revenue increase and 49.7% operating margins, while Novo Nordisk offers better valuation (3x lower P/E ratio) and higher dividend yield (4.8% vs 0.6%). The author favors Eli Lilly for growth-oriented investors despite its premium valuation. | View source ↗ | The Motley Fool | Oct 6, 2026 | bullish | 0.4 | 1 |
| Freehand CEO Nitin Jayakrishnan Addresses Supply Chain Disruption and Resilience at LogiPharma USA 2026 | Freehand, an AI workforce platform for procurement and accounts payable operations, showcased its solutions at LogiPharma USA 2026. CEO Nitin Jayakrishnan participated in a keynote panel discussing supply chain resilience in the pharmaceutical industry. The company, which serves major healthcare enterprises including Johnson & Johnson and Pfizer, recently raised $75 million in funding to scale its AI Teams that automate complex procurement and spend management processes. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | neutral | 0 | 1 |
| Freehand CEO Nitin Jayakrishnan Addresses Supply Chain Disruption and Resilience at LogiPharma USA 2026 | Freehand, an AI workforce platform for procurement and accounts payable operations, showcased its solutions at LogiPharma USA 2026. CEO Nitin Jayakrishnan participated in a keynote panel discussing supply chain resilience in the pharmaceutical industry. The company, which serves major healthcare enterprises including Johnson & Johnson and Pfizer, recently raised $75 million in funding to scale its AI Teams that automate complex procurement and spend management processes. | View source ↗ | GlobeNewswire Inc. | Oct 6, 2026 | neutral | 0 | 1 |
| Cardinal Health (CAH) Outperforms Broader Market: What You Need to Know | Cardinal Health closed at $233.12, up 2.11% and outpacing the S&P 500's 0.66% gain. However, the stock has fallen 7.64% over the past month, lagging the Medical sector. The company is expected to report earnings on November 5, 2026, with predicted EPS of $2.92 (up 14.51% YoY) and revenue of $66.96 billion (up 4.6% YoY). Cardinal Health holds a Zacks Rank of #3 (Hold) with a Forward P/E of 18.19, trading at a premium to its industry average. | View source ↗ | Zacks Investment Research | Oct 5, 2026 | neutral | 0 | 1 |
| Cardinal Health, Inc. (CAH) Stock forecasts - Yahoo Finance UK | Cardinal Health, Inc. (CAH) Stock forecasts Yahoo Finance UK | View source ↗ | Yahoo Finance UK | Oct 5, 2026 | neutral | 0 | 0.6 |
| Cardinal Health, Inc. (CAH) Stock Forecasts - Yahoo! Finance Canada | Cardinal Health, Inc. (CAH) Stock Forecasts Yahoo! Finance Canada | View source ↗ | Yahoo! Finance Canada | Oct 5, 2026 | neutral | 0 | 0.6 |
| Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| Zacks Industry Outlook Highlights McKesson, Cardinal Health, Becton, Dickinson, Merit Medical Systems and ProDex | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, and technology adoption, with the global market expected to reach $318.77 billion by 2031. However, tariffs, commodity inflation, and policy-driven pricing changes present headwinds. Five key stocks—McKesson, Cardinal Health, Becton Dickinson, Merit Medical Systems, and ProDex—are highlighted as well-positioned to capitalize on favorable industry trends through 2026. | View source ↗ | Zacks Investment Research | Oct 2, 2026 | bullish | 0.8 | 1 |
| 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.6 | 1 |
| 5 Medical Dental Supply Stocks to Watch as Industry Prospects Improve | The Medical-Dental Supplies industry is positioned for growth driven by specialty care, biologics, GLP-1 therapies, AI automation, and aging demographics. The global medical supplies market is expected to reach $318.77 billion by 2031 with a 10% CAGR. However, tariffs, commodity inflation, and pharmaceutical pricing changes remain headwinds. Key industry players show mixed near-term prospects with the industry trading at favorable valuations compared to broader markets. | View source ↗ | Zacks Investment Research | Oct 1, 2026 | bullish | 0.6 | 1 |
| A pharmaceutical distributor, Cardinal Health, plans to release first-quarter results before trading opens Nov. 5. - Stock Titan | A pharmaceutical distributor, Cardinal Health, plans to release first-quarter results before trading opens Nov. 5. Stock Titan | View source ↗ | Stock Titan | Oct 1, 2026 | neutral | 0 | 0.6 |
| Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade - Yahoo Finance | Cardinal Health (CAH) Stock Slides as Market Rises: Facts to Know Before You Trade Yahoo Finance | View source ↗ | Yahoo Finance | Sep 25, 2026 | neutral | 0 | 0.6 |
| Cardinal Health (CAH) Stock Looks About Right At Today’s Price - Yahoo Finance | Cardinal Health (CAH) Stock Looks About Right At Today’s Price Yahoo Finance | View source ↗ | Yahoo Finance | Sep 24, 2026 | neutral | 0 | 0.6 |
| CVS vs. CAH: Which Healthcare Services Stock Is the Better Pick Now? - Yahoo Finance | CVS vs. CAH: Which Healthcare Services Stock Is the Better Pick Now? Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| Cardinal Health (CAH) Stock Moves -1.64%: What You Should Know - Yahoo Finance | Cardinal Health (CAH) Stock Moves -1.64%: What You Should Know Yahoo Finance | View source ↗ | Yahoo Finance | Sep 22, 2026 | neutral | 0 | 0.6 |
| 2 Profitable Stocks with Solid Fundamentals and 1 We Turn Down - StockStory | 2 Profitable Stocks with Solid Fundamentals and 1 We Turn Down StockStory | View source ↗ | StockStory | Aug 24, 2026 | neutral | 0 | 0.6 |
| Cardinal Health (CAH) Stock Richly Valued Despite $5b Cash Flow Strength - Simply Wall Street | Cardinal Health (CAH) Stock Richly Valued Despite $5b Cash Flow Strength Simply Wall Street | View source ↗ | Simply Wall Street | Aug 12, 2026 | neutral | 0 | 0.6 |
Informational research only, not financial advice. Forecasts are uncertain and can be wrong.